InvestSMART

Integral Diagnostics Limited (ASX:IDX)

ALERT: Price-sensitive ASX Announcement for IDX
Current share price for IDX : $2.230 -0.05 (-2.19%)+
Announcement
Release
25 Aug 2026 9:14AM
Price at Release
$2.280
Full Release
download
Summary
Integral Diagnostics Limited's FY26 Full Year Investor Presentation highlights significant financial growth and strategic advancements. Operating EBITDA increased by 30.3% to AUD 164.8 million, with a revenue rise of 25.6% to AUD 788.7 million. The growth is attributed to increased patient volumes, Medicare indexation, and enhanced service mix. The company's strategic focus includes the merger with Capitol Health, which contributed to the financial results post-acquisition on December 20, 2024. Capital expenditure during FY26 was AUD 49.8 million, aimed at expanding and enhancing medical equipment and facilities across various regions. Net debt stood at AUD 298.9 million, with a stable debt-to-EBITDA ratio, and significant liquidity headroom of AUD 117.0 million. The presentation also highlights industry growth drivers such as an aging population, advancements in AI, and regulatory changes expected to benefit IDX in the coming years.
Key Points
  • Operating EBITDA increased by 30.3% to AUD 164.8 million.
  • Revenue grew by 25.6% to AUD 788.7 million due to increased patient volumes and service mix.
  • Merger with Capitol Health contributed significantly to FY26 financial results.
  • Capital expenditure was AUD 49.8 million aimed at facility and equipment enhancements.
  • Net debt at AUD 298.9 million with strong liquidity position.
  • Industry growth driven by aging population and technological advancements.
  • Strategic focus on expanding MRI and CT services post regulatory changes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.